The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn).
https://european-biotechnology.com/wp-content/uploads/2024/04/Ipsen_headquarters.__c__Ipsen_SA.jpg183275Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-04-23 08:40:002024-06-13 13:24:18Ipsen puts US$1.8bn in pipeline expansion in movement disorders
French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
https://european-biotechnology.com/wp-content/uploads/2024/04/National_Eye_Institute.png11502532Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-04-22 12:32:082024-06-13 13:25:47Seabelife SAS to develop next-gen dry AMD drug
Finnish Faron Pharmaceuticals Ltd. announces the appointment of Yrjö Wichmann as Interim Chief Financial Officer. He took over the role in mid-April because his predecessor James O’Brien is leaving Faron to take up another job opportunity outside the company.
Waste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).
Vaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.
https://european-biotechnology.com/wp-content/uploads/2024/04/HIV_.jpeg8601157Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-04-17 07:17:002024-06-13 13:31:15Naobios and Sumagen partner to develop HIV vaccine
Finnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland.
https://european-biotechnology.com/wp-content/uploads/2024/04/Adrenomed.png10381572Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-04-11 07:47:482024-05-07 11:23:06Shock: Adrenomed AG gets FDA fast track designation
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
New Chief Business Officer for Amarna Therapeutics
AppointmentsLeiden-based Amarna Therapeutics welcomed Aurelia Caparrós as its new Chief Business Officer (CBO) in April.
Swiss Biotech Report reporting record turnover
Latest NewsThe Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn).
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Latest NewsIpsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.
Seabelife SAS to develop next-gen dry AMD drug
Latest NewsFrench drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
Faron Pharmaceuticals with Interim CFO
AppointmentsFinnish Faron Pharmaceuticals Ltd. announces the appointment of Yrjö Wichmann as Interim Chief Financial Officer. He took over the role in mid-April because his predecessor James O’Brien is leaving Faron to take up another job opportunity outside the company.
AmphiStar BV secures €6m to expand production
Latest NewsWaste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).
Naobios and Sumagen partner to develop HIV vaccine
Latest NewsVaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.
Solar Foods starts Factory01
Latest NewsFinnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland.
Shock: Adrenomed AG gets FDA fast track designation
Latest NewsGerman AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity.
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Latest NewsALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.